Jump to content

Empathogen

From Wikipedia, the free encyclopedia
(Redirected from Entactogenic)
A selection of MDMA pills, which are often nicknamed "Ecstasy" or "E"
Part of a series on
Psychedelia
Arts

Psychedelic film

Culture
Drugs
Experience
History
Law
Related topics

Empathogens or entactogens are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, relatedness, emotional openness—that is, empathy or sympathy—as particularly observed and reported for experiences with 3,4-methylenedioxymethamphetamine (MDMA).[1] This class of drug is distinguished from the classes of hallucinogen or psychedelic, and amphetamine or stimulants. Major members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, GHB, αMT, and αET, MDAI among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its counterparts, the term MDxx is often used (with the exception of MDPV). Entactogens are sometimes incorrectly referred to as hallucinogens or stimulants, although many entactogens such as ecstasy exhibit psychedelic or stimulant properties as well.[2]

Etymology

[edit]

The term empathogen, meaning "generating a state of empathy", was coined in 1983–84 by Ralph Metzner as a term to denote a therapeutic[citation needed] class of drugs that includes MDMA and phenethylamine relatives.[3] David E. Nichols in 1986 rejected this initial terminology and adopted, instead, the term entactogen, meaning "producing a touching within", to denote this class of drugs, asserting a concern with the potential for improper association of the term empathogen with negative connotations related to the Greek root πάθος páthos ("suffering; passion").[4] Additionally, Nichols wanted to avoid any association with the term pathogenesis.[5] Nichols also thought the original term was limiting, and did not cover other therapeutic uses for the drugs that go beyond instilling feelings of empathy.[6] The hybrid word entactogen is derived from the roots en (Greek: within), tactus (Latin: touch) and -gen (Greek: produce).[4] Entactogen is not becoming dominant in usage, and, despite their difference in connotation, they are essentially interchangeable, as they refer to precisely the same chemicals.

In 2024, an additional alternative term, connectogen, was proposed and introduced.[7]

Psychological effects

[edit]

Both terms adopted and used in naming the class of therapeutic drugs for MDMA and related compounds were chosen with the intention of providing some reflection of the reported psychological effects associated with drugs in the classification and distinguishing these compounds from classical psychedelic drugs such as LSD, mescaline, and psilocybin and major stimulants, such as methamphetamine and amphetamine.[6] Chemically, MDMA is classified as a substituted amphetamine (which includes stimulants like dextroamphetamine and psychedelics like 2,5-dimethoxy-4-methylamphetamine), which makes MDMA a substituted phenethylamine (which includes other stimulants like methylphenidate and other psychedelics like mescaline) by the definition of amphetamine. While chemically related both to psychedelics and stimulants, the psychological effects experienced with MDMA were reported to provide obvious and striking aspects of personal relatedness, feelings of connectedness, communion with others, and ability to feel what others feel—in short an empathic resonance is consistently evoked.[8] While psychedelics like LSD may sometimes yield effects of empathic resonance, these effects tend to be momentary and likely passed over on the way to some other dimension or interest. In contrast, the main characteristic that distinguishes MDMA from LSD-type experiences is the consistency of the effects of emotional communion, relatedness, emotional openness—in short, empathy and sympathy.[6]

Mechanism of action

[edit]

Entactogens like MDMA are serotonin releasing agents and hence are indirect agonists of serotonin receptors.[9][10][11] They produce entactogenic effects in animals such as increased prosocial behavior like adjacent lying, enhanced empathy-like behavior, and antiaggressive effects.[9][12][13] Likewise, MDMA increases sociability, prosociality, and emotional empathy in humans.[13]

In animals, MDMA induced prosocial behavior and elevations in circulating oxytocin levels and these effects were abolished by pretreatment with the serotonin 5-HT1A receptor antagonist WAY-100635.[9][14][15][16][17] Conversely, the serotonin 5-HT1A receptor agonist 8-OH-DPAT produced prosocial behavior and increased oxytocin levels similarly to MDMA.[9][15][18] In addition, MDMA has been shown to activate oxytocinergic neurons in the hypothalamus and this too is reversed by serotonin 5-HT1A receptor antagonism.[9][15][19] Subsequent research found that direct injection of the serotonin 5-HT1A receptor WAY-100635 locally into the basolateral amygdala (BLA) suppressed MDMA-induced prosocial behavior and that direct injection of MDMA locally into the BLA significantly increased sociability.[20][16]

The serotonin 5-HT2B and 5-HT2C receptor antagonist SB-206553 has also been found to block MDMA-induced prosocial behavior, although it produced potentially confounding thigmotaxis (hyperactivity at periphery of testing chamber) as well.[14][17] Conversely, the serotonin 5-HT1B receptor antagonist GR-55562 and the serotonin 5-HT2A receptor antagonist ketanserin were both ineffective.[14][16][17] Likewise, another study found that selective antagonists of the serotonin 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT4 receptors (SB-216641), volinanserin (MDL-100907), SB-242084, and SB-204070, respectively) were all ineffective in suppressing MDMA-induced prosocial activity.[20][16] Other research has found that serotonin 5-HT2B receptor inactivation abolishes the serotonin release induced by MDMA and attenuates many of its effects.[10][11][21] In addition to the preceding findings, induction of serotonin release by MDMA in the nucleus accumbens and consequent activation of serotonin 5-HT1B receptors in this area is implicated in its enhancement of prosocial behaviors, whereas consequent activation of yet-to-be-determined serotonin receptors in this area is implicated in its enhancement of empathy-like behaviors.[22][12][23][24] Injection of the serotonin 5-HT1B receptor antagonist NAS-181 directly into the nucleus accumbens blocked the prosocial behaviors of MDMA.[23]

On the basis of the serotonin 5-HT1A receptor-mediated oxytocin release with MDMA, it has been proposed that increased oxytocinergic signaling may mediate the prosocial effects of MDMA in animals.[9][15] Accordingly, intracerebroventricular injection of the peptide oxytocin receptor antagonist tocinoic acid blocked MDMA- and 8-OH-DPAT-induced prosocial effects.[9][15][25] However, in a subsequent study, systemically administered C25, a non-peptide oxytocin receptor antagonist, failed to affect MDMA-induced prosocial behavior, whereas the vasopressin V1A receptor antagonist relcovaptan (SR-49059) was able to block MDMA-induced prosocial activity.[9][25] It might be that tocinoic acid is non-selective and also blocks the vasopressin V1A receptor or that C25 is peripherally selective and is unable to block oxytocin receptors in the brain.[9][25] More research is needed to clarify this.[25][9] In any case, in another study, the non-peptide and centrally active selective oxytocin receptor antagonist L-368899 abolished MDMA-induced prosocial behavior.[25][26] Conversely, in other studies, different oxytocin receptor antagonists were ineffective.[23]

As in animals, MDMA greatly increases circulating oxytocin levels in humans.[9] Serotonin reuptake inhibitors and norepinephrine reuptake inhibitors reduced the subjective effects of MDMA in humans, for instance increased extroversion, self-confidence, closeness, openness, and talkativeness.[13] The 5-HT2A receptor antagonist ketanserin reduced MDMA-induced increases in friendliness.[13] MDMA-induced emotional empathy was not affected by the serotonin 5-HT1A receptor antagonist pindolol or by intranasal oxytocin.[27] Similarly, MDMA-induced emotional empathy and prosocial behavior have not been associated with circulating oxytocin levels.[27][9] As such, the role of oxytocin in the entactogenic effects of MDMA in humans is controversial.[9]

Other serotonin releasing agents, like fenfluramine, show prosocial effects in animals similar to those of MDMA.[28][23] Fenfluramine has likewise been reported to improve social deficits in children with autism.[23][29] Selective agonists of the serotonin 5-HT1A and 5-HT1B receptors and of the oxytocin receptors have been or are being investigated for the potential treatment of social deficits and aggression.[30][31][32][33] Examples include batoprazine, eltoprazine (DU-28853), fluprazine (DU-27716), F-15,599 (NLX-01), zolmitriptan (ML-004), and LIT-001.[32][33][34] Serotonergic psychedelics, for instance lysergic acid diethylamide (LSD) and psilocybin, which act as non-selective serotonin receptor agonists including of the serotonin 5-HT1 and 5-HT2 receptors, have shown prosocial and empathy-enhancing effects in animals and/or humans as well, both acutely and long-term.[35][36][37]

The serotonin release of MDMA appears to be the key pharmacological action mediating the entactogenic, prosocial, and empathy-enhancing effects of the drug.[13][38][39] However, in addition to serotonin release, MDMA is also a potent releasing agent of norepinephrine and dopamine, and hence acts as a well-balanced serotonin–norepinephrine–dopamine releasing agent.[38][39] Additionally, MDMA is a direct agonist of several serotonin receptors, including of the serotonin 5-HT2 receptors, with moderate affinity.[38][39] These actions are thought to play an important role in the effects of MDMA, including in its psychostimulant, euphoriant, and mild psychedelic effects, as well as in its unique and difficult-to-replicate "magic".[38][40][39][41] It has been said by Matthew Baggott that few to no MDMA analogues, including MBDB, methylone, 6-APDB, 5-APDB, 6-APB, 5-APB, MDAT, and MDAI among others, reproduce the full quality and "magic" of MDMA.[40][42] Exceptions may anecdotally include 5-MAPB, particularly in specific enantiomer ratios, and the Borax combo.[40][42][43] The unique properties of MDMA are believed to be dependent on a very specific mixture and ratio of pharmacological activities, including combined serotonin, norepinephrine, and dopamine release and direct serotonin receptor agonism.[40][42]

Examples

[edit]
See also: Substituted methylenedioxyphenethylamine

The chemicals below have a varying degree of entactogenic effects; some of them induce additional effects, including serenic effects, stimulant effects, antidepressant effects, anxiolytic effects, and psychedelic effects.[5]

Phenethylamines

[edit]

Substituted amphetamines

[edit]

Substituted aminorexes

Cathinones

Tryptamines

[edit]

Aminoindanes

[edit]

Therapeutic uses

[edit]

Psychiatrists began using entactogens as psychotherapy tools in the 1970s despite the lack of clinical trials.[44] In recent years, the scientific community has been revisiting the possible therapeutic uses of entactogens. Therapeutic models using MDMA have been studied because of its entactogenic properties.[45] This type of therapy would be applicable for treating a patient who was experiencing psychological trauma such as PTSD. Traumatic memories can be linked to fear in the patients which makes engaging with these memories difficult. Administration of an entactogen such as MDMA allows the patient to disconnect from the fear associated with the traumatic memories and engage in therapy.[45] MDMA acts by targeting the body's stress response in order to cause this therapeutic effect. In addition to reducing anxiety and a conditioned fear response, MDMA also reduces the avoidance of feelings.[45] Patients are then able to trust themselves and their therapist and engage with traumatic memories under the influence of MDMA.

Although the therapeutic effects of entactogens may be promising, drugs such as MDMA have the potential for negative effects that are counter productive in a therapy setting. For example, MDMA may make negative cognition worse. This means that a positive experience is not a guarantee and can be contingent on aspects like the setting and the patient's expectations.[46] Additionally there is no clear model of the psychopharmacological means for a positive or negative experience.[46] There is also a potential concern for the neurotoxic effects of MDMA on the fiber density of serotonin neurons in the neocortex. High doses of MDMA may cause potential depletion of serotonergic axons. The same effects may not be caused by lower doses of MDMA required for treatment, however.[47]

References

[edit]
  1. ^ M., Colman, Andrew (2015). A dictionary of psychology. Oxford University Press. ISBN 9780199657681. OCLC 896901441.{{cite book}}: CS1 maint: multiple names: authors list (link)
  2. ^ McGregor, Iain S.; Thompson, Murray R.; Callaghan, Paul D. (2010-01-01). Stolerman, Ian P. (ed.). Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg. pp. 758–762. doi:10.1007/978-3-540-68706-1_154. ISBN 9783540686989.
  3. ^ Metzner, Ralph; Adamson, Sophia (2001). Julie Holland (ed.). Ecstasy : the complete guide ; a comprehensive look at the risks and benefits of MDMA. Rochester, Vt: Park Street Press. p. 182. ISBN 978-0-89281-857-0.
  4. ^ a b Nichols, D. (1986). "Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens". Journal of Psychoactive Drugs. 18 (4): 305–13. doi:10.1080/02791072.1986.10472362. PMID 2880944.
  5. ^ a b Colman, Andrew M. (2015). Dictionary of Psychology - Oxford Reference. doi:10.1093/acref/9780199657681.001.0001. ISBN 9780199657681.
  6. ^ a b c Nichols, D; Yensen, R; Metzner, R; Shakespeare, W (1993). "The Great Entactogen - Empathogen Debate". Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS. 4 (2): 47–49. Retrieved 6 January 2015.
  7. ^ Stocker K, Liechti ME (August 2024). "Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile "the great entactogen-empathogen debate"". J Psychopharmacol. 38 (8): 685–689. doi:10.1177/02698811241265352. PMC 11311894. PMID 39068642.
  8. ^ Metzner, Ralph (1993). "Letter from Ralph Metzner". Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS. 4 (1). Retrieved 8 January 2015.
  9. ^ a b c d e f g h i j k l m Dunlap LE, Andrews AM, Olson DE (October 2018). "Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine". ACS Chem Neurosci. 9 (10): 2408–2427. doi:10.1021/acschemneuro.8b00155. PMC 6197894. PMID 30001118.
  10. ^ a b Martinez-Price, Diana; Krebs-Thomson, Kirsten; Geyer, Mark (1 January 2002). "Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies". Addiction Research & Theory. 10 (1). Informa UK Limited: 43–67. doi:10.1080/16066350290001704. ISSN 1606-6359.
  11. ^ a b Stove CP, De Letter EA, Piette MH, Lambert WE (August 2010). "Mice in ecstasy: advanced animal models in the study of MDMA". Curr Pharm Biotechnol. 11 (5): 421–433. doi:10.2174/138920110791591508. PMID 20420576.
  12. ^ a b Rein B, Raymond K, Boustani C, Tuy S, Zhang J, St Laurent R, Pomrenze MB, Boroon P, Heifets B, Smith M, Malenka RC (April 2024). "MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens". Sci Adv. 10 (17): eadl6554. Bibcode:2024SciA...10L6554R. doi:10.1126/sciadv.adl6554. PMC 11042730. PMID 38657057.
  13. ^ a b c d e Kamilar-Britt P, Bedi G (October 2015). "The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals". Neurosci Biobehav Rev. 57: 433–446. doi:10.1016/j.neubiorev.2015.08.016. PMC 4678620. PMID 26408071.
  14. ^ a b c Blanco-Gandía MC, Mateos-García A, García-Pardo MP, Montagud-Romero S, Rodríguez-Arias M, Miñarro J, Aguilar MA (September 2015). "Effect of drugs of abuse on social behaviour: a review of animal models". Behav Pharmacol. 26 (6): 541–570. doi:10.1097/FBP.0000000000000162. PMID 26221831.
  15. ^ a b c d e Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")". Neuroscience. 146 (2): 509–514. doi:10.1016/j.neuroscience.2007.02.032. PMID 17383105.
  16. ^ a b c d Esaki H, Sasaki Y, Nishitani N, Kamada H, Mukai S, Ohshima Y, Nakada S, Ni X, Deyama S, Kaneda K (May 2023). "Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice". Eur J Pharmacol. 946: 175653. doi:10.1016/j.ejphar.2023.175653. PMID 36907260.
  17. ^ a b c Morley KC, Arnold JC, McGregor IS (June 2005). "Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat". Prog Neuropsychopharmacol Biol Psychiatry. 29 (5): 648–657. doi:10.1016/j.pnpbp.2005.04.009. PMID 15908091.
  18. ^ Tan O, Martin LJ, Bowen MT (July 2020). "Divergent pathways mediate 5-HT1A receptor agonist effects on close social interaction, grooming and aggressive behaviour in mice: Exploring the involvement of the oxytocin and vasopressin systems". J Psychopharmacol. 34 (7): 795–805. doi:10.1177/0269881120913150. PMID 32312154.
  19. ^ Hunt GE, McGregor IS, Cornish JL, Callaghan PD (August 2011). "MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635". Brain Res Bull. 86 (1–2): 65–73. doi:10.1016/j.brainresbull.2011.06.011. PMID 21745546.
  20. ^ a b Heifets BD, Olson DE (January 2024). "Therapeutic mechanisms of psychedelics and entactogens". Neuropsychopharmacology. 49 (1): 104–118. doi:10.1038/s41386-023-01666-5. PMC 10700553. PMID 37488282.
  21. ^ Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (March 2008). "Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro". J Neurosci. 28 (11): 2933–2940. doi:10.1523/JNEUROSCI.5723-07.2008. PMC 6670669. PMID 18337424.
  22. ^ Nichols DE (2022). "Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated". Front Psychiatry. 13: 863088. doi:10.3389/fpsyt.2022.863088. PMC 8990025. PMID 35401275.
  23. ^ a b c d e Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, Walsh JJ, Sze JY, Malenka RC (December 2019). "Distinct neural mechanisms for the prosocial and rewarding properties of MDMA". Sci Transl Med. 11 (522). doi:10.1126/scitranslmed.aaw6435. PMC 7123941. PMID 31826983.
  24. ^ Walsh JJ, Llorach P, Cardozo Pinto DF, Wenderski W, Christoffel DJ, Salgado JS, Heifets BD, Crabtree GR, Malenka RC (October 2021). "Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD". Neuropsychopharmacology. 46 (11): 2000–2010. doi:10.1038/s41386-021-01091-6. PMC 8429585. PMID 34239048.
  25. ^ a b c d e Wronikowska-Denysiuk O, Mrozek W, Budzyńska B (February 2023). "The Role of Oxytocin and Vasopressin in Drug-Induced Reward-Implications for Social and Non-Social Factors". Biomolecules. 13 (3): 405. doi:10.3390/biom13030405. PMC 10046619. PMID 36979340.
  26. ^ Kuteykin-Teplyakov K, Maldonado R (November 2014). "Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice". Eur Neuropsychopharmacol. 24 (11): 1773–1783. doi:10.1016/j.euroneuro.2014.08.007. hdl:10230/23309. PMID 25241352.
  27. ^ a b Kuypers KP, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, Ramaekers JG (2014). "No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation". PLOS ONE. 9 (6): e100719. Bibcode:2014PLoSO...9j0719K. doi:10.1371/journal.pone.0100719. PMC 4074089. PMID 24972084.
  28. ^ Behera HK, Joga R, Yerram S, Karnati P, Mergu T, Gandhi K, M S, Nathiya D, Singh RP, Srivastava S, Kumar S (September 2024). "Exploring the regulatory framework of psychedelics in the US & Europe". Asian J Psychiatr. 102: 104242. doi:10.1016/j.ajp.2024.104242. PMID 39305768.
  29. ^ Aman MG, Kern RA (July 1989). "Review of fenfluramine in the treatment of the developmental disabilities". J Am Acad Child Adolesc Psychiatry. 28 (4): 549–565. doi:10.1097/00004583-198907000-00014. PMID 2670881.
  30. ^ de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". Eur J Pharmacol. 526 (1–3): 125–139. doi:10.1016/j.ejphar.2005.09.065. PMID 16310183.
  31. ^ Olivier B (December 2004). "Serotonin and aggression". Ann N Y Acad Sci. 1036 (1): 382–392. Bibcode:2004NYASA1036..382O. doi:10.1196/annals.1330.022. PMID 15817750.
  32. ^ a b Felthous AR, McCoy B, Nassif JB, Duggirala R, Kim E, Carabellese F, Stanford MS (2021). "Pharmacotherapy of Primary Impulsive Aggression in Violent Criminal Offenders". Front Psychol. 12: 744061. doi:10.3389/fpsyg.2021.744061. PMC 8716452. PMID 34975633.
  33. ^ a b Sałaciak K, Pytka K (November 2021). "Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?". Pharmacol Ther. 227: 107872. doi:10.1016/j.pharmthera.2021.107872. PMID 33905796.
  34. ^ Nashar PE, Whitfield AA, Mikusek J, Reekie TA (2022). "The Current Status of Drug Discovery for the Oxytocin Receptor". Oxytocin. Methods Mol Biol. Vol. 2384. pp. 153–174. doi:10.1007/978-1-0716-1759-5_10. ISBN 978-1-0716-1758-8. PMID 34550574.
  35. ^ Markopoulos A, Inserra A, De Gregorio D, Gobbi G (2021). "Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder". Front Pharmacol. 12: 749068. doi:10.3389/fphar.2021.749068. PMC 8846292. PMID 35177979.
  36. ^ Bhatt KV, Weissman CR (February 2024). "The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects". npj Ment Health Res. 3 (1): 7. doi:10.1038/s44184-023-00053-8. PMC 10955966. PMID 38609500.
  37. ^ Kupferberg A, Hasler G (2024). "From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression". Front Psychiatry. 15: 1372650. doi:10.3389/fpsyt.2024.1372650. PMC 11513289. PMID 39469469.
  38. ^ a b c d Halberstadt, Adam L.; Nichols, David E. (2020). "Serotonin and serotonin receptors in hallucinogen action". Handbook of Behavioral Neuroscience. Vol. 31. Elsevier. p. 843–863. doi:10.1016/b978-0-444-64125-0.00043-8. ISBN 978-0-444-64125-0.
  39. ^ a b c d Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493.
  40. ^ a b c d Baggott M (23 June 2023). Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine. PS2023 [Psychedelic Science 2023, June 19-23, 2023, Denver, Colorado]. Denver, CO: Multidisciplinary Association for Psychedelic Studies.
  41. ^ Heal DJ, Gosden J, Smith SL, Atterwill CK (March 2023). "Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines". Neuropharmacology. 225: 109375. doi:10.1016/j.neuropharm.2022.109375. PMID 36529260.
  42. ^ a b c "Better Than Ecstasy: Progress in Developing a Novel Class of Therapeutic with Matthew Baggott, PhD". YouTube. 6 March 2024. Retrieved 20 November 2024.
  43. ^ "Advantageous benzofuran compositions for mental disorders or enhancement". Google Patents. 8 December 2022. Retrieved 21 November 2024.
  44. ^ Malamud, Ozer, Yvette; Yuri, Ito (2010-01-01). Encyclopedia of emotion. Greenwood Press. ISBN 9780313345746. OCLC 934324453.{{cite book}}: CS1 maint: multiple names: authors list (link)
  45. ^ a b c Caiuby, Labate, Beatriz; Clancy, Cavnar (2014-01-01). The therapeutic use of Ayahuasca. Springer. ISBN 9783642404252. OCLC 876696992.{{cite book}}: CS1 maint: multiple names: authors list (link)
  46. ^ a b Parrott, A. C. (2007-04-01). "The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review". Psychopharmacology. 191 (2): 181–193. doi:10.1007/s00213-007-0703-5. ISSN 0033-3158. PMID 17297639. S2CID 40322032.
  47. ^ F., Quenzer, Linda (2013-05-06). Psychopharmacology : drugs, the brain, and behavior. Sinauer. ISBN 9780878935109. OCLC 869923492.{{cite book}}: CS1 maint: multiple names: authors list (link)

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Empathogen&oldid=1258738722"